DESCRIPTION OF THE COLLABORATION Sample Clauses

DESCRIPTION OF THE COLLABORATION. (a) The Parties wish to collaborate on the activities set out below to achieve the objectives of the Programme: (i) Identify and establish a pipeline of RNA-based vaccines for development, including new targets and areas for improvement to the RNA platform technology (e.g. targeting and structural stability). (ii) Establish processes for the development of RNA-based vaccines and the improvement of the RNA platform technology. (iii) Improve the formulation of RNA-based vaccines, including testing new lipids synthesised as a part of the Programme’s New Lipids Discovery Initiative. (iv) Support and facilitate the technology transfer (including technical assistance) of RNA- based vaccines and/or the RNA platform technology from Bio-Manguinhos to the partners of the Programme, as requested. (v) Support and produce data comparing the use of methyl-pseudouridine and pseudouridine in the manufacturing of preventive RNA-based vaccines and therapeutics based on RNA platform technology. (b) The Parties will continue to explore possibilities to expand the Collaboration in relation to the Programme.
Sample 1
AutoNDA by SimpleDocs
DESCRIPTION OF THE COLLABORATION. 1.1 The Parties wish to ensure the development, registration, distribution, and uptake of Target Products through this Collaboration. In order to achieve this objective, the Parties agree to: 1.1.1 Engage with potential funders to finance the development of Target Products for affordable supply to children in need of treatment for MDR-TB ("Target Population"); 1.1.2 At an appropriate time, by mutual agreement, enter into license agreement(s) needed to facilitate the development, commercialization and availability ofTarget Products in the Target Population; 1.1.2.1 The Parties acknowledge that in face of a small and highly fragmented market, it remains a challenge not only to develop pediatric formulations of MDR-TB medicines but also to ensure such formulations reach the children in need in an affordable and sustainable manner. For this reason, the Parties will negotiate in good faith for a territorial coverage serving as many countries with MDR-XX xxxxxx as possible, ideally globally; 1.1.3 Support the development and regulatory approval of Target Products working closely with one or more manufacturer(s); 1.1.4 Support the work of relevant and interested public health stakeholders with appropriate information to facilitate use and uptake of Target Products in the Target Population; 1.2 Responsibilities of the Parties
Sample 1
DESCRIPTION OF THE COLLABORATION. 2.1 VBI and Brii Bio wish to collaborate on the development of a Hepatitis B recombinant protein based immunotherapeutic in the Licensed Territory. This collaboration will initially focus on the execution of a Development Plan by the Parties with the objective of developing a Novel Composition and comparing such Novel Composition to VBI-2601 in the Collaboration Clinical Trial. Brii Bio will select the Brii Bio Adjuvant [*****] within five (5) days of the Effective Date. Based on the results of such Pre-clinical Studies, Brii Bio will select the Novel Compositions to be included in the Collaboration Clinical Trial subject to Section 4.4. Once selected, INDs for the Novel Composition and the VBI-2601 candidate will be filed in the Licensed Territory and, if approved, the Novel Composition and the VBI-2601 candidate will be tested in the Collaboration Clinical Trial, after which, Brii Bio will have the right to select either the Novel Composition or VBI-2601 for further clinical development in support of an application for Marketing Approval in the Licensed Territory.
Sample 1
DESCRIPTION OF THE COLLABORATION. 2.1 VBI wishes to outlicense the development and commercialization of Licensed Product in the Licensed Territory to Brii Bio.
Sample 1
DESCRIPTION OF THE COLLABORATION. In order to start a collaboration with the Supplier, the Influencer must register to the platform by entering email and password or using social accounts. After receiving confirmation, he/she can enter all the required data and specifically: name, surname and date of birth. At the time of registration, the Influencer will enter his/her data giving all the consents and statements required by the platform. In case the Influencer is a minor but at least sixteen years of age, he/she must give all the consents and statements required by the platform. In the event that the Influencer is under 16 years old, the parents or guardian must enter their full details and the Influencer’s details, giving and must give consent and statements required by the platform and accept these terms and conditions. The Influencer, registering to the platform, guarantees to: - comply with all legal and contractual regulations applicable to these Terms and Conditions; - be the legitimate owner of the data entered, to be considered true, correct and updated; - not to attempt to falsely increase his/her performance, or the performance of any other influencer, in order to unduly increase the results of promotions; - truthfulness promote goods or services and not for the sole purpose of increasing the performance of his/her own profile; - always follow the promotional indications of Clients and not deviating from what is indicated; - to always respect the usage rules that will be published on the dedicated page of the xxxxxxx.xxx website. The Influencer receives by means of notifications on the platform, an invitation to participate to the influencer marketing campaign. The influencer can accept or decline on the basis of the offered compensation, which will be calculated taking in consideration the KPIs. The notification will contain the name of the Client, the kind of campaign and the related activities to be carried out, whether there are materials or not, which social networks are required by the Client for the campaign, the content of the campaign, supporting materials, start and end date, maximum budget invested by the Client.
Sample 1
DESCRIPTION OF THE COLLABORATION. The Parties wish to accomplish the following objectives through this Collaboration: a) Licensing of Abacavir and Abacavir-containing formulations for paediatric HIV treatment. b) If and when ViiV receives FDA or EMA approval for any of its current pipeline products, such products for paediatric HIV treatment will be eligible to be licensed to the MPPF for the same territorial scope of the Abacavir licence agreement referenced in sub-clause (a), subject to agreement of the terms of such licence. c) The Parties acknowledge that in the field of paediatric HIV treatment, there are formulations for which access to patents alone is likely not to be sufficient for rapid development and access to paediatric formulations of ARVs. In such cases the Parties further agree that (i) formulation development and manufacturing technology transfers, (ii) access to regulatory data, and (iii) partnerships that develop new fixed dose combinations (FDCs) can all serve as catalysts (“Catalytic Interventions”) for development of products that would otherwise not be developed. ViiV and the MPPF are committed to collaborate on the use of such Catalytic Interventions to improve access to paediatric HIV products, including, but not limited to, approaching third parties with relevant IP and/or expertise for the development of needed paediatric ARV formulations. d) Both Parties will seek to support the development of generic manufactured paediatric products in a manner consistent with World Health Organisation pre-qualification standards or the standards of a Stringent Regulatory Authority to optimise access and scale up of paediatric treatment. e) Where novel ARVs formulations are developed by MPPF licensees, ViiV and MPPF will explore further mechanisms to ensure their availability outside the defined licensed territory to as many children in need as possible. f) MPPF will carry out detailed research to define the clinical unmet product(s) and formulation(s) need within the existing paediatric treatment landscape for ViiV’s products to be used for paediatric HIV treatment and will share such research with ViiV. g) MPPF will identify appropriate generic manufacturing or other partners that have the R&D, manufacturing and/or commercial capabilities to produce and supply paediatric products derived using ViiV’s patents and Catalytic Interventions at prices that will facilitate access to such products, and will provide to ViiV such supporting information as ViiV reasonably requests to su...
Sample 1
DESCRIPTION OF THE COLLABORATION. Theory of Action
Sample 1
AutoNDA by SimpleDocs

Related to DESCRIPTION OF THE COLLABORATION

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

  • Collaboration 31.1 If the Buyer has specified in the Order Form that it requires the Supplier to enter into a Collaboration Agreement, the Supplier must give the Buyer an executed Collaboration Agreement before the Start date. 31.2 In addition to any obligations under the Collaboration Agreement, the Supplier must: 31.2.1 work proactively and in good faith with each of the Buyer’s contractors 31.2.2 co-operate and share information with the Buyer’s contractors to enable the efficient operation of the Buyer’s ICT services and G-Cloud Services

  • License of Intellectual Property Each Party (a “Licensor”) grants the other Party (a “Licensee”) the non-exclusive, royalty-free, paid-up, worldwide, irrevocable, right, during the term of this Agreement, to use the Licensor’s Intellectual Property solely for the purposes of this Agreement and to carry out the Party’s functions consistent with its responsibilities and authority as set forth in the enable legislation and regulations. Such licenses shall not give the Licensee any ownership interest in or rights to the Intellectual Property of the Licensor. Each Licensee agrees to abide by all third-party license and confidentiality restrictions or obligations applicable to the Licensor’s Intellectual Property of which the Licensor has notified the Licensee in writing.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!